Arbitrary Unit - PowerPoint PPT Presentation

1 / 4
About This Presentation
Title:

Arbitrary Unit

Description:

Supplemental Figure 1. Specific siRNA treatments suppress the mRNA expression of each PLC isoform in MIN-6 cells Non-targeting (NT) siRNA (open bars; n=5) or siRNA ... – PowerPoint PPT presentation

Number of Views:77
Avg rating:3.0/5.0
Slides: 5
Provided by: Suzu6
Category:
Tags: arbitrary | unit

less

Transcript and Presenter's Notes

Title: Arbitrary Unit


1
Supplemental Figure 1. Specific siRNA treatments
suppress the mRNA expression of each PLC isoform
in MIN-6 cells Non-targeting (NT) siRNA (open
bars n5) or siRNA specific for each PLC
isoform (closed bar n5) was applied to MIN-6
cells. After a 48 hr incubation, cells were
subjected to RT-PCR analysis. PLC expression
levels in MIN-6 cells were quantified and
normalized relative to ß-actin mRNA levels. P
lt0.05, P lt0.01 versus NT siRNA-transfected
MIN-6 cells assessed by unpaired t test. Data
are presented as means SEM.
PLCß2
PLCß1
PLCß3



Arbitrary Unit
Arbitrary Unit
Arbitrary Unit
PLCß1
NT
siRNA
NT
siRNA
NT
siRNA
PLCß2
PLCß3
PLC?2
PLCd1
PLC?1



Arbitrary Unit
Arbitrary Unit
Arbitrary Unit
PLC?1
NT
siRNA
NT
siRNA
NT
siRNA
PLC?2
PLCd1
2
Supplemental Figure 2. Specific siRNA treatments
suppress the protein levels of PLC-ß1 and PLC-?1
isoforms in MIN-6 cells Non-targeting (NT) siRNA
or siRNA specific for each PLC-ß1 and PLC-?1
isoforms were applied to MIN-6 cells. After a 48
hr incubation, immunoblot analysis was performed
with MIN-6 cells lysate, using a monoclonal anti-
PLCß1 antibody (sc-5291, Santa Cruz) or a
polyclonal anti- PLC?1 antibody (2822, Cell
Signaling).
3
Supplemental Table 1. The oligonucleotide primers
used for RT-PCR.
4
Supplemental Table 2. Effects of several
pretreatments on insulin content of MIN-6 cells
and isolated islets Insulin contents of MIN-6
cells (1-5106 cells/well) and isolated islets
(10 islets/well) used in the experiments are
indicated. Left column shows the Figure numbers
corresponding to each pretreatments. Data are
presented as means SEM.
Insulin content (ng)
Pretreatments
Fig.
IL-6 (-) IL-6 ()
IL-6 1200 pg/ml (isolated islets) 426.5 25.4 450.7 17.4
IL-6 600 pg/ml (isolated islets) 426.5 25.4 479.5 34.5
vehicle (isolated islets) 241.7 43.1 208.6 24.0
U-73122 (isolated islets) 198.5 57.3 171.7 35.0
IL-6 1200 pg/ml 6 hr (MIN-6) 3025.0 34.1 3094.2 181.1
IL-6 1200 pg/ml 24 hr (MIN-6) 3277.3 63.4 3190.1 165.6
IL-6 1200 pg/ml 48 hr (MIN-6) 2909.9 73.0 2776.7 62.3
NT siRNA (MIN-6) 4683.9 100.6 5238.1 62.0
IL-6R siRNA (MIN-6) 4032.1 198.9 4844.1 196.1
Vehicle (MIN-6) 1342.5 175.4 1232.3 195.9
U-73122 (MIN-6) 1529.1 39.8 1426.3 21.2
Neomycin (MIN-6) 1645.9 41.4 1585.9 24.3
NT siRNA (MIN-6) 2702.0 97.7 2816.2 129.0
PLC ß1 siRNA (MIN-6) 2899.0 18.9 3171.5 19.0
PLC ß2 siRNA (MIN-6) 2556.5 72.3 2915.4 169.3
PLC ß3 siRNA (MIN-6) 2389.7 36.8 2594.7 78.2
PLC ?1 siRNA (MIN-6) 3004.8 71.6 2875.3 56.7
PLC ?2 siRNA (MIN-6) 2378.7 92.0 2664.1 100.9
PLC d1 siRNA (MIN-6) 2881.5 65.8 3138.3 43.5
Vehicle (MIN-6) 3700.5 75.5 3721.5 51.6
H-89 (MIN-6) 3442.3 74.3 3700.0 96.4
Vehicle (MIN-6) 1506.2 24.1 1461.4 35.9
Xestospongin C (MIN-6) 762.3 14.9 675.7 139.7
Write a Comment
User Comments (0)
About PowerShow.com